title: Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma.
abstract: The clinicopathological significance of HER-1- and HER-2-overexpressions (OE) (HercepTest score 2+ or 3+) in biliary cancer and their relationship to the efficacy of adjuvant chemotherapy (ACT) were assessed. In 72 biliary cancer (28 gallbladder and 44 bile duct cancer), HER-1 and HER-2 were stained immunohistochemically in formalin-fixed, paraffin-embedded specimens. The ACT included uracil and tegafur (UFT)-based chemotherapies. Out of the 72 cancer, OE was observed in 31 specimens (43%) for HER-1 and 47 (65%) for HER-2. However, their OEs were not correlated with each other. HER-2-OE was inversely correlated with the clinical stage (p=0.0482). HER-1-OE was correlated with distant metastasis (p=0.0263), but not with the clinical stage. Neither the OE of HER-1 or HER-2, nor their co-expression, showed any significant effect in term of patient survival. In the HER-1-OE (-) patients, the survival rate of the ACT group was significantly higher than that of the surgery-alone (SA) group (p=0.0423), but in the HER-1-OE (+) patients, there was no statistical difference in survival rate between the ACT and the SA group. In contrast, HER-2-OE had no significant effect on the efficacy of ACT. Multivariate analysis also demonstrated that the histological grade and ACT were significant variables, but T, N, M and HER-1 and HER-2 were not significant variables. In conclusion, neither HER-1-OE or HER-2-OE were prognostic factors of the biliary cancer. However, HER-1-OE may be a useful marker for the indication of ACT.
authors.affiliation: Department of Cardiovascular and Digestive Surgery, Shimane University School of Medicine, Izumo, Japan.
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Ogo
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nio
authors.forename: Seiji
authors.initials: S
authors.lastname: Yano
authors.forename: Tomoko
authors.initials: T
authors.lastname: Toga
authors.forename: Makoto
authors.initials: M
authors.lastname: Koike
authors.forename: Koji
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Masayuki
authors.initials: M
authors.lastname: Itakura
authors.forename: Riruke
authors.initials: R
authors.lastname: Maruyama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001650:Bile Duct Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D017734:Bile Ducts, Extrahepatic; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D017024:Chemotherapy, Adjuvant; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases